TIDMABC
RNS Number : 6652Z
ABCAM PLC
14 January 2020
14 January 2020
ABCAM PLC
("Abcam" or "the Group")
Appointment of Chief Financial Officer
Abcam plc ("Abcam" or "the Company", AIM: ABC), a global leader
in the supply of life science research tools, is pleased to
announce the appointment of Michael Baldock as Chief Financial
Officer with effect from 3 February 2020*.
Michael assumes the role of Chief Financial Officer from Gavin
Wood, who notified the Company on 22 July 2019 of his intention to
step down from the Board once a successor had been identified.
Michael has over 30 years of relevant functional and sector
experience acquired through senior leadership roles at HSBC,
Lazard, Bentley Health Care and SG Warburg. He is a founding
partner at Ondra Partners, an independent financial advisory firm
which has advised Abcam for several years. The Board believe that
his experience, deep sector expertise and knowledge of Abcam make
him an ideal candidate to lead Abcam's financial and strategic
growth plans.
Peter Allen, Chairman of Abcam, said: "Following an extensive
and thorough process, the Board was unanimous in its view that
Michael is the right candidate to join Abcam. We have known and
trusted Michael for several years and I am pleased that we have
been able to attract him to join us."
Alan Hirzel, Chief Executive Officer of Abcam, added: "Michael's
experience will be valuable for us as we deliver our strategy. His
energy and passion for our business will fit well with our teams.
We are excited to welcome Michael to the business."
Michael Baldock commented: "I am excited to be joining Abcam on
the next stage of its journey. Having worked closely with Alan and
the team, I have been impressed by the Company and its potential. I
am looking forward to working with Alan, the Executive Leadership
Team and the Board in implementing the Company's strategic vision
and delivering continued long term, profitable growth."
Michael will be appointed to the Board on 3 February 2020, and
Gavin Wood will step down on this date.
*Michael Baldock's appointment will be subject to receiving the
necessary approval from the UK Home Office allowing him to work in
the UK.
AIM Rules disclosures
Full name: Michael Shaun Baldock
Age: 56
Director and / or partner roles held in the five years preceding
his appointment at Abcam:
Current Directorships / Partnerships Previous Directorships / Partnerships
Ondra LLP (Partner)
======================================
Michael does not currently have an interest in shares in
Abcam.
Save as disclosed above there are no additional disclosures to
be made in accordance with Schedule Two paragraph (g) of the AIM
Rules.
For further information, please contact:
Abcam
+ 44 (0) 1223 696 000
James Staveley, VP, Investor Relations
J.P.Morgan Cazenove - Nominated Advisor & Corporate
Broker
+ 44 (0) 20 7742 4000
James Mitford / Hemant Kapoor
Numis - Joint Corporate Broker
+44 (0) 20 7260 1000
Garry Levin / Duncan Monteith
FTI Consulting
+ 44 (0) 20 3727 1000
Ben Atwell / Natalie Garland-Collins
Notes:
The Nomination Committee appointed a leading executive search
and board advisory consulting firm to conduct the search for a new
Chief Financial Officer. An extensive Global search was conducted,
and a shortlist of candidates was agreed before interviews were
conducted.
About Abcam plc
As a global life sciences company, Abcam identifies, develops,
and distributes high-quality biological reagents and tools that are
crucial to research, drug discovery and diagnostics. Working across
the industry, the Company supports life scientists to achieve their
mission, faster.
Abcam partners with life science organisations to co-create
novel binders for use in drug discovery, in vitro diagnostics and
therapeutics, driven by the Company's proprietary discovery
platforms and world-leading, antibody expertise.
By constantly innovating its binders and assays, Abcam is
helping advance the global understanding of biology and causes of
disease, which enables new treatments and improved health. The
Company's pioneering data-sharing approach gives scientists
increased confidence in their results by providing validation, user
comments and peer-reviewed citations for its 110,000 products.
With eleven sites globally, many of Abcam's 1,100 strong team
are located in the world's leading life science research hubs,
complementing a global network of services and support. Abcam was
admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFZGMMRFLGGZM
(END) Dow Jones Newswires
January 14, 2020 02:00 ET (07:00 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024